Inhalation and oral drug delivery technologies

Skyepharma has a range of proprietary inhalation and oral drug delivery technologies that have been used in many different products that are approved in over 80 countries, from the US and Europe to Japan and South America.

Skyepharma’s proprietary inhalation formulation and device technologies for Dry Powder Inhalers (DPIs) and Metered Dose Inhalers (MDIs) are designed to enable excellent lung delivery and improved patient adherence. In addition to ensuring robust and consistent performance, they also provide patent protection. 

> Find out more

Our wide range of validated oral modified-release technologies allow modified release, pulsed release, timed release or delivery to the colon. The technologies can offer clinical benefits to patients as well as offering proprietary protection to the product. They are widely used in many approved products and are adaptable to a wide range of different products.

> Find out more

All of Skyepharma’s technologies are backed by the know-how of professional experts who have the capabilities and resources to undertake and support their application in product development from feasibility to commercial production.

Range of oral modified release and inhalation pharmaceutical products developed by Skyepharma

Copyright 2014, Skyepharma. All Rights Reserved. Skyepharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom

Contact addresses

Skyepharma PLC
46-48 Grosvenor Gardens
London
SW1W 0EB
UK

Tel: +44 207 881 0524

Fax: +44 207 881 1199

E-mail us

Skyepharma AG
Eptingerstrasse 61
4132 Muttenz
Switzerland

Tel: +41 61 467 5555

Fax: +41 61 467 5500

E-mail us

This website works best using cookies.